Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 May 9;15(10):2671.
doi: 10.3390/cancers15102671.

Advances in Lung Cancer Therapy

Domenico Galetta  1   2
Affiliations
Editorial

Advances in Lung Cancer Therapy

Domenico Galetta. Cancers (Basel). .

Abstract

Lung cancer, including both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), remains one of the most aggressive types of cancer, and the prognosis for individuals diagnosed with this neoplasm has, for the most part, been insufficient [...].

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

References

    1. Rodak O., Peris-Díaz M.D., Olbromski M., Podhorska-Okołów M., Dzięgiel P. Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. Cancers. 2021;13:4705. doi: 10.3390/cancers13184705. - DOI - PMC - PubMed
    1. Liao T., Deng J., Chen W., Xu J., Yang G., Zhou M., Lv Z., Wang S., Song S., Tan X., et al. Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation. Cancers. 2022;14:4709. doi: 10.3390/cancers14194709. - DOI - PMC - PubMed
    1. Jiang S., Huang J., He H., Liu Y., Liang L., Sun X., Li Y., Cong L., Qing B., Jiang Y. NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma. Cancers. 2022;14:4395. doi: 10.3390/cancers14184395. - DOI - PMC - PubMed
    1. Misri S., Kaul K., Mishra S., Charan M., Verma A.K., Barr M.P., Ahirwar D.K., Ganju R.K. Cannabidiol Inhibits Tumorigenesis in Cisplatin-Resistant Non-Small Cell Lung Cancer via TRPV2. Cancers. 2022;24:1181. doi: 10.3390/cancers14051181. - DOI - PMC - PubMed
    1. Refeno V., Lamuraglia M., Terrisse S., Bonnet C., Dumont C., Doucet L., Pouessel D., Culine S. Survival of Patients with Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small Cell Lung Cancer Treated beyond the Second Line in the Tyrosine Kinase Inhibitor Era. Cancers. 2021;13:3887. doi: 10.3390/cancers13153887. - DOI - PMC - PubMed

Publication types

LinkOut - more resources